Patient P1 showed a positive clinical response to IL-6 blockade using tocilizumab, a monoclonal antibody targeting IL-6R, consistent with outcomes observed in another patient with RIPK1 variant-associated autoimmunity (71, 72). The gene discussed is RIPK1; the disease is Autoimmunity.